IL17A and cancer: As shown in Figure 11, the enrichment pathways of the characteristic compounds were mainly concentrated in the lipids and atherosclerosis, chagas disease, fluid shear stress and atherosclerosis, proteoglycans in cancer, IL-17 signaling pathway, sphingolipid signaling pathway, diabetic cardiomyopathy, arginine and proline metabolism, etc., among which the lipid and atherosclerosis pathways were more enriched and 11 characteristic compounds could better affect the expression levels of IL-1, TNFα, CD36, IL-1β, etc. (Figure 12).